Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block

Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block


Rafael Henrique | Lightrocket | Getty Images

Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina’s acquisition of cancer test developer Grail while the Federal Trade Commission fights to unwind the deal. 

The groups filed 14 amicus briefs Monday urging the U.S. 5th Circuit Court of Appeals to reverse an FTC order that would have Illumina undo the $7.1 billion Grail deal over concerns that it stifles competition. Last week, the San Diego-based DNA sequencing company appealed the agency’s ruling.

The proponents of the deal argued in court filings that the FTC overstepped its authority in trying to unwind the merger that closed nearly two years ago. They added that blocking the companies from merging could harm the development of life-saving technology.

“Unaccountable federal agency power undermines liberty, and overzealous, unfair agency enforcement impedes technological advancements benefitting citizens’ wellbeing,” attorneys general from 12 states said in one of the briefs. 

Those states are Alaska, Arkansas, Georgia, Idaho, Indiana, Iowa, Kentucky, Louisiana, Nebraska, South Carolina, Utah and Virginia. 

Thirty-four Republican lawmakers touted Grail’s early screening test, which can detect more than 50 types of cancers through a single blood draw. The test isn’t approved by the Food and Drug Administration, but it has raked in limited sales over the past year.

Grail needs Illumina to obtain regulatory approval and commercialize production of the test, which are “required steps to delivering the full benefits of these tests to the public and detecting cancer as quickly as possible,” the lawmakers argued. 

The FTC declined to comment on the filings.  

The deal has faced broad opposition: Last year the European Union’s executive body, the European Commission, blocked the acquisition citing similar competition concerns. Illumina has appealed that order. 

And, activist investor Carl Icahn, who holds a 1.4% stake in Illumina, launched a proxy fight with the company over the Grail deal. 

Illumina shareholders voted to oust the chair of its board late last month. The company’s CEO Francis deSouza stepped down on Sunday after weeks of harsh backlash from Icahn.

Icahn’s opposition stemmed from Illumina’s decision to close the acquisition without approval from antitrust regulators.



Source

Business class+? Delta says segmentation is coming to high-end cabins
Business

Business class+? Delta says segmentation is coming to high-end cabins

Nurphoto | Nurphoto | Getty Images Delta Air Lines is studying new types of airplane tickets — this time in the premium cabins at the front of the plane. Airlines spent years slicing up their coach cabins, from extra legroom seats to bare-bones basic economy fares that don’t allow changes or include a seat assignment. […]

Read More
Trump’s tariffs on Brazil could make your coffee even more expensive
Business

Trump’s tariffs on Brazil could make your coffee even more expensive

President Donald Trump’s proposed 50% tariff on Brazilian imports is bad news for coffee drinkers. Brazil, the largest U.S. supplier of green coffee beans, accounts for about a third of the country’s total supply, according to data from the U.S. Department of Agriculture. Coffee beans need to grow in a warm, tropical climate, making Hawaii […]

Read More
Space startup Varda raises 7 million in funding to make drugs in orbit
Business

Space startup Varda raises $187 million in funding to make drugs in orbit

Pavlo Gonchar | Lightrocket | Getty Images Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space. The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. […]

Read More